TY  - JOUR
AU  - Mateos, María-Victoria
AU  - Martínez-López, Joaquín
AU  - Hernández, Miguel-Teodoro
AU  - Ocio, Enrique-M
AU  - Rosiñol, Laura
AU  - Martínez, Rafael
AU  - Teruel, Ana-Isabel
AU  - Gutiérrez, Norma C
AU  - Martín Ramos, María-Luisa
AU  - Oriol, Albert
AU  - Bargay, Joan
AU  - Bengoechea, Enrique
AU  - González, Yolanda
AU  - Pérez de Oteyza, Jaime
AU  - Gironella, Mercedes
AU  - Encinas, Cristina
AU  - Martín, Jesús
AU  - Cabrera, Carmen
AU  - Paiva, Bruno
AU  - Cedena, María-Teresa
AU  - Puig, Noemí
AU  - Bladé, Joan
AU  - Lahuerta, Juan-José
AU  - San-Miguel, Jesús
PY  - 2015
DO  - 10.1182/blood-2015-08-666537
UR  - http://hdl.handle.net/10668/10516
T2  - Blood
AB  - Bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexamethasone (Rd) are 2 standards of care for elderly untreated multiple myeloma (MM) patients. We planned to use VMP and Rd for 18 cycles in a sequential or alternating...
LA  - en
KW  - Aged
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bortezomib
KW  - Dexamethasone
KW  - Female
KW  - Humans
KW  - Lenalidomide
KW  - Male
KW  - Melphalan
KW  - Multiple Myeloma
KW  - Prednisone
KW  - Thalidomide
KW  - Treatment Outcome
TI  - Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
TY  - research article
VL  - 127
ER  -